ストックスクリーナーアプリを入手
1.455
7.78%
0.105
アフターアワーズ：
1.45
-0.005
-0.34%
前日終値:
$1.35
開ける：
$1.33
24時間の取引高:
6.63M
Relative Volume:
1.33
時価総額：
$246.69M
収益：
当期純損益:
$-175.43M
株価収益率:
-0.7372
EPS:
-1.9736
ネットキャッシュフロー:
$-143.28M
1週間 パフォーマンス:
-9.63%
1か月 パフォーマンス:
-29.71%
6か月 パフォーマンス:
-50.00%
1年 パフォーマンス:
-47.85%
1日の値動き範囲:
$1.32
$1.455
1週間の範囲:
$1.32
$1.555
52週間の値動き範囲:
$1.32
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Compare CABA vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.455 | 246.69M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 再開されました | Jefferies | Buy |
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Cabaletta Bio Slides As Insider Purchases Lose Another US$60k - Webull
Cabaletta Bio Slides As Insider Purchases Lose Another US$60k - Simply Wall Street
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - www.marketscreener.com
Press Release: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Cabaletta Bio (Nasdaq:CABA)Stock Analysis - Simply Wall Street
Form 8K Cabaletta Bio Inc For: 14 September By Investing.com - Investing.com India
$2.50 share warrants bring new cash to Cabaletta Bio (CABA) - Stock Titan
Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration - Investing.com
Form 8K Cabaletta Bio Inc For: 14 September By Investing.com - Investing.com UK
Cabaletta Bio warrant exercises bring $128.2M gross proceeds after June 2025 offering - TradingView
Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale By Investing.com - Investing.com Canada
Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale By Investing.com - Investing.com UK
Cactus Cuts Q3 Pressure Control Outlook on Expected Double-Digit Revenue Decline - Minichart
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors - MyChesCo
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
CABA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16 - GuruFocus
Cabaletta Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio Inc. (CABA) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Cabaletta (CABA) Earnings Reading: EPS Lands Above Forecast in the Current Update; Post-Report: Shares Finish 0.96% Down in the Available RecordProfit Growth Outlook - vinanet.vn
Blue Owl Capital Holdings LP Acquires New Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner - Endpoints News
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Trading 10.3% HigherShould You Buy? - MarketBeat
Norges Bank Initiates New Position in Cabaletta Bio (CABA) With 8.7 Million Share Purchase - GuruFocus
Cabaletta Bio (CABA) Rallies 5% as Biotech Sentiment ImprovesForce Index - vinanet.vn
HC Wainwright Raises Earnings Estimates for Cabaletta Bio - MarketBeat
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA) - The Globe and Mail
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - Kalkine
Cabaletta Bio Releases Q2 2026 Financial Results - AlphaStreet
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com Canada
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com South Africa
Why is Cabaletta Bio stock sliding today? - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Canada
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
Cabaletta Bio Inc (CABA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
5.91%
2.85%
大文字化:
|
ボリューム (24 時間):